
Shattuck Labs (STTK) Stock Forecast & Price Target
Shattuck Labs (STTK) Analyst Ratings
Bulls say
Shattuck Labs Inc is well-positioned for growth in the biotechnology sector, particularly through its innovative product pipeline that includes the first-in-class SL-325 antibody aimed at treating inflammatory bowel disease (IBD) and other inflammatory conditions. The increasing adoption of biologics in the treatment of ulcerative colitis (UC) and Crohn's disease (CD)—with usage rates rising significantly from 2007 to 2015—indicates a growing market that Shattuck Labs aims to penetrate with its cutting-edge therapies. Additionally, the company's conservative sales growth estimates for SL-325 reflect a solid foundation for future revenue generation, underpinned by a projected robust market share increase for effective agents in the therapeutic landscape.
Bears say
Shattuck Labs Inc faces significant challenges in the development of its lead programs, particularly the SL-325 and SL-425 candidates, as there are concerns regarding their potential efficacy, immunogenicity, and safety, which could hinder their market uptake. Furthermore, the biotechnology company operates in an environment where market growth and the adoption of advanced therapies for inflammatory bowel disease are consistently underestimated, complicating its revenue outlook. Additionally, the increasing utilization of existing biologics suggests a competitive landscape that may further limit Shattuck Labs’s ability to capture market share, casting doubt on the commercial viability of its drug candidates.
This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.
Shattuck Labs (STTK) Analyst Forecast & Price Prediction
Start investing in Shattuck Labs (STTK)
Order type
Buy in
Order amount
Est. shares
0 shares